IT 901

Drug Profile

IT 901

Alternative Names: IT-901

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator ImmuneTarget
  • Class Antineoplastics; Small molecules
  • Mechanism of Action NF kappa B kinase inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Multiple myeloma; Multiple sclerosis

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 10 Aug 2016 IT 901 is available for licensing as of 10 Aug 2016. http://www.immunetarget.com/
  • 10 Aug 2016 Preclinical trials in Chronic lymphocytic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top